dc.contributor.author |
Bauer, MK |
en |
dc.contributor.author |
Breier, Bernhard |
en |
dc.contributor.author |
Bloomfield, Francis |
en |
dc.contributor.author |
Jensen, EC |
en |
dc.contributor.author |
Gluckman, Peter |
en |
dc.contributor.author |
Harding, Jane |
en |
dc.date.accessioned |
2016-11-24T23:05:26Z |
en |
dc.date.available |
2002-12-17 |
en |
dc.date.issued |
2003-04 |
en |
dc.identifier.citation |
Journal of Endocrinology, April 2003, 177 (1), 83 - 92 |
en |
dc.identifier.issn |
0022-0795 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/31140 |
en |
dc.description.abstract |
Intra-uterine growth restriction (IUGR) is a major cause of perinatal mortality and morbidity. Postnatally, growth hormone (GH) increases growth, increases circulating insulin-like growth factor (IGF)-I levels, and alters metabolism. Our aim was to determine if GH infusion to IUGR fetal sheep would alter fetal growth and metabolism, and thus provide a potential intra-uterine treatment for the IUGR fetus. We studied three groups of fetuses: control, IUGR+ vehicle and IUGR+GH (n=5 all groups). IUGR was induced by repeated embolisation of the placental vascular bed between 110 and 116 days of gestation (term=145 days). GH (3.5 mg/kg/day) or vehicle was infused in a pulsatile manner from 117 to 127 days of gestation. Embolisation reduced fetal growth rate by 25% (P<0.01) and reduced the weight of the fetal liver (20%), kidney (23%) and thymus (31%; all P<0.05). GH treatment further reduced the weight of the fetal kidneys (32%) and small intestine (35%; both P<0.04), but restored the relative weight of the fetal thymus and liver (P<0.05). Embolisation decreased fetal plasma IGF-I concentrations (48%, P<0.001) and increased IGF binding protein 1 (IGFBP-1) concentrations (737%, P<0.002). GH treatment restored fetal plasma IGF-I concentrations to control levels, while levels in IUGR+vehicle fetuses stayed low (P<0.05 vs control). IGFBP-1 and IGFBP-2 concentrations were about sevenfold lower in amniotic fluid than in fetal plasma, but amniotic and plasma concentrations were closely correlated (r=0.75, P<0.0001 and r=0.55 P<0.0001 respectively). Embolisation transiently decreased fetal blood oxygen content (40%, P<0.002), and increased blood lactate concentrations (213%, P<0.04). Both returned to pre-embolisation levels after embolisation stopped, but blood glucose concentrations declined steadily in IUGR+vehicle fetuses. GH treatment maintained fetal blood glucose concentrations at control levels. Our study shows that GH infusion to the IUGR fetal sheep restores fetal IGF-I levels but does not improve fetal growth, and further reduces the fetal kidney and intestine weights. Thus, fetal GH therapy does not seem a promising treatment stratagem for the IUGR fetus. |
en |
dc.description.uri |
https://www.ncbi.nlm.nih.gov/labs/articles/12697039/ |
en |
dc.language |
English |
en |
dc.publisher |
Society for Endocrinology |
en |
dc.relation.ispartofseries |
Journal of Endocrinology |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0022-0795/
http://www.endocrinology-journals.org/site/misc/Bioscientifica_Open_Access_Policy.xhtml |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Chronic pulsatile infusion of growth hormone to growth-restricted fetal sheep increases circulating fetal insulin-like growth factor-I levels but not fetal growth |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1677/joe.0.1770083 |
en |
pubs.issue |
1 |
en |
pubs.begin-page |
83 |
en |
pubs.volume |
177 |
en |
dc.description.version |
VoR - Version of Record |
en |
dc.identifier.pmid |
12697039 |
en |
pubs.author-url |
http://joe.endocrinology-journals.org/content/177/1/83.abstract |
en |
pubs.end-page |
92 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
62540 |
en |
pubs.org-id |
Liggins Institute |
en |
pubs.org-id |
LiFePATH |
en |
dc.identifier.eissn |
1479-6805 |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
12697039 |
en |